secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001628280-23-014914
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q1 net income $8.1M vs loss; raises FY revenue guidance to $42-46M
----------------------------------------------------------------------------

- Net income $8.1M ($0.11 diluted EPS) vs net loss $13.2M ($0.32 loss) in Q1 2022.
- Total revenue $11.1M, down from $12.3M YoY; excluding prior Sympazan sales, revenue +10%.
- Non-GAAP adjusted EBITDA loss improved to $3.9M from $8.1M.
- Raises FY2023 guidance: revenue $42-46M (prev. $37-41M); adj EBITDA loss $24-28M (prev. $31-36M).
- Two shareholder lawsuits dismissed with prejudice in April 2023; brand name Anaphylm conditionally accepted by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/0001628280-23-014914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/aqst-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-014914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer